Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 10.77
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
Buy
Sell